Albireo Pharma competitors

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

Richard A Miller is a co-founder, the president, and chief executive officer of [Corvus Pharmaceuticals](https://www.crunchbase.com/organization/corvus-pharmaceuticals#/entity), a clinical-stage biopharmaceutical company focused on the development of novel agents. Previously, he co-founded Pharmacyclics and served the same company as the chief executive officer. At Pharmacyclics, he led the initial discovery and development efforts for ibrutinib. Prior to co-founding Pharmacyclics, Miller co-founded IDEC and held various leadership roles as vice president and director at the same company. He has also founded other private and public biotech companies. Miller holds a Doctor of Medicine degree, summa cum laude, from the State University of New York Medical School and is currently Adjunct Clinical Professor of Medicine at Stanford University Medical Center.

Ryan Spencer is a Board Member at Dynavax Technologies and Chief Executive Officer at Dynavax Technologies and is based in Berkeley, California. He has worked as Senior Director Commercial Operations at Dynavax Technologies; Senior Product Director, HEPLISAV-B at Dynavax Technologies; and Vice President, Corporate Strategy & Commercial Operations at Dynavax Technologies. Ryan attended Universidade Federal de Santa Catarina between 1995 and 1999.

Mr. Onsi has served as our Chief Financial Officer, Treasurer and Secretary since our inception in 2011. Mr. Onsi has been at HealthCare Ventures since 2007, including serving as a managing director since 2009 and the chief executive officer of Tensha Therapeutics, Inc. which was sold to Roche Holdings, Inc. in 2016. Prior to joining HealthCare Ventures, Mr. Onsi was at Genzyme Corporation, or Genzyme, where he served in roles as Vice President, Campath Product Operations and Portfolio Management, Oncology from 2005 to 2007 and as Vice President, Business Development from 2004 to 2005. Prior to Genzyme, he was Chief Financial Officer of Tolerx, Inc., a venture capital funded biotechnology company, from 2001 to 2004. Before joining Tolerx, Inc., he was in business development at LeukoSite, a publicly traded biopharmaceutical company that was acquired by Millennium Pharmaceuticals, Inc. He began his career as an attorney at Bingham Dana LLP. Mr. Onsi currently serves as a member of the board of directors of Vaxxas Pty Ltd., a privately-held biotechnology company. He received a Juris Doctor degree from the University of Michigan Law School and a B.S. in biological sciences from Cornell University.

John Kollins is a President/CEO/Co-Founder at SATSUMA PHARMACEUTICALS INC, Board Member at SATSUMA PHARMACEUTICALS INC, and Advisor at Covx and is based in South San Francisco, California. He has experience at ATHENA NEUROSCIENCES INC and Elan Pharmaceutical and has worked as Chief Operating Officer at Oxigene Inc, Vice President at SurroMed, and Advisor To CEO at SurroMed. John works or has worked as Consultant at Covx, CHAIRMAN at CovX Research LLC, and Consultant at Entelos. He studied at Duke University between 1981 and 1985 and University of Virginia Darden School of Business between 1987 and 1989.

Dror has extensive managerial and transactional expertise, He was previously with ProSeed Capital, a European corporate finance boutique. Dror is a graduate of the University of Oxford (M.Jur.) and completed LL.M. studies at Harvard University. At Harvard, Dror was also a Fulbright Scholar focusing on the pharmaceutical industry and markets, an Olin Fellow for Law, Economics and Business, and an Economics Teaching Fellow at Harvard’s Economics Department. Dror received an LL.B. with distinction (First Class Honours) from the University of Leicester.

New drugs that make a differenceSpecialties: Drug Discovery & Development;Accretion & Development of Biotech Talent;Research: Neuroendocrinology, Structural Pharmacology, Medicinal Chemistry, Reproductive Medicine, Endocrinology, Biophysics & Computational Chemistry, Receptor Pharmacology & Biology

Dr. James Breitmeyer is the president & CEO Oncternal Therapeutics, Inc., a San Diego cancer biotechnology company. He was instrumental in identifying and acquiring rights to ROR1 technology from UCSD and for developing ETS-family inhibitors based on discoveries from Georgetown University, while assembling Oncternal’s pipeline of oncology therapeutics. Dr. Breitmeyer was a lead author on the research grant submitted to the California Institute for Regenerative Medicine (CIRM) which resulted in the award of $18.3 million to UCSD to support development of lead program cirmtuzumab currently in Phase 1/2 clinical studies. Dr. Breitmeyer believes biomedical research and collaborations with academia are essential for targeting cancers where there are patients with critical unmet needs that aren’t being fully addressed by currently available therapies. At Oncternal, Dr. Breitmeyer is combining drug development expertise with exciting science for a synergistic combination to spur the development of novel product candidates that can potentially be applied across a large number of cancers. Dr. Breitmeyer is board certified in internal medicine and oncology. He holds a bachelor’s degree in chemistry from the University of California and earned M.D. and Ph.D. degrees from Washington University School of Medicine with fellowships at Washington University and Harvard Medical School. He held clinical and teaching faculty positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer has more than 30 years of experience across all aspects of the biotechnology industry in both large and small companies, and across multiple therapeutic areas. He is currently a member of the Boards of Directors of Oncternal Therapeutics Inc, Zogenix Inc, and Otonomy Inc.